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Abstract
Background: Type 1 neurofibromatosis (NF-1) is an autosomal dominant disorder with variable
penetrance; approximately 50% of cases present as new mutations
Case report: We report a case of a 56 year-old man with Von Recklinghausen's disease,
carcinoma of the ampulla of Vater and incidental benign gastrointestinal stromal tumours of the
jejunum.
Conclusions: Coexistence between ampullary carcinoid, ectopic pancreatic tissue in the jejunum
and neurofibroma of the jejunum in NF-1 has been previously described however; the association
of synchronous carcinoma of the ampulla of Vater and gastrointestinal stromal tumour of the
jejunum in NF-1 has not been previously reported.
Background
Type 1 neurofibromatosis (NF-1) is an autosomal domi-
nant disorder with variable penetrance; approximately
50% of the cases present as new mutations. The major
diagnostic criterion includes multiple cutaneous neurofi-
bromas, axillary or inguinal freckling, café au lait spots,
Lisch nodules (pigmented iris hamartomas) and a first-
degree family history of NF-1 [1]. The gene for NF-1 has
been identified on chromosome 17. NF-1 gene encodes a
GTPase activating protein that has the potential to regu-
late the activity of the p21 product of the ras oncogene
and the gene has been suggested to play an important role
in controlling cell proliferation and differentiation in a
wide range of tissues [2]. Gastrointestinal tract lesions are
not uncommon in NF-1, and typically vary from gut neu-
ral tissue hyperplasia to gastrointestinal stromal and
endocrine cell tumours; there are only rare reports of a
miscellaneous group of other malignant neoplasms [3].
Gastrointestinal stromal tumours (GIST) have been histo-
logically identified as neurofibromas, leiomyomas, leio-
myosarcomas, schwannomas, autonomic nerve tumours
(GANT) and stromal tumours without any definite nerve
or muscular differentiation, which have been hypothe-
sised as originating from interstitial cells of Cajal (ICC) [3-
6]. Gastrointestinal lesions associated with NF-1,
although usually asymptomatic, may present as
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abdominal pain, dyspepsia, vomiting, anaemia, melaena,
haematemesis, haematochezia, intussusception, volvulus,
small bowel obstruction, fever and abdominal mass. The
case reported by Karatzas et al., [7] mentions the coexist-
ence between ampullary carcinoid, ectopic pancreatic tis-
sue in the jejunum and neurofibroma of the jejunum in
NF-1. The association of synchronous carcinoma of the
ampulla of Vater and gastrointestinal stromal tumour of
the jejunum in NF-1 has not been previously described.
Case Report
A 56-year-old man presented with history of obstructive
jaundice. ERCP done two months earlier at the referring
hospital showed a distal bile duct stricture that was
stented. Jaundice had initially improved but recurred due
to stent occlusion. Skin examination was remarkable for
diffuse cutaneous neurofibromas and café au lait spots. CT
scan showed a mass lesion in pancreatic head with no evi-
dence of metastatic disease elsewhere. There was no histo-
logical/cytological diagnosis before the operation. With a
provisional diagnosis of carcinoma head of the pancreas
patient underwent laparotomy. At laparotomy, several
nodules were seen on the serosal surface of the small
bowel of which three yellowish serosal nodules from the
jejunum were excised. A pylorus-preserving proximal pan-
creatic-duodenectomy was performed. Pathological
examination of the resected pancreas showed a 33 mm,
moderately differentiated invasive adenocarcinoma (Fig-
ure 1), arising from a severely dysplastic villous adenoma
of the ampulla. Two intra-pancreatic lymph nodes
showed metastatic carcinoma with extranodal spread
(pT4N1bM0). The three small bowel serosal nodules were
less than 5 mm in size and had similar appearances.
Microscopically the lesions were composed of bland spin-
dle cells arranged in a storiform pattern set within muscle
wall (Figure 2a). No necrosis, mitotic figures or pleomor-
phism was seen. Tumour cells were positive for CD117
(Figure 2b) and CD34 (Figure 2d) but were negative for
S100 protein (Figure 2c), neurofilament, synaptophysin,
Photomicrograph showing pancreatic adenocarcinoma (Haematoxylin and Eosin × 100) Figure 1
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desmin, smooth muscle actin and calponin. These fea-
tures were of benign gastrointestinal stromal tumours.
Postoperative period was uneventful. The patient was
offered adjuvant therapy but refused it. Local recurrence
was detected at one-year follow-up.
Discussion
Gastrointestinal (GI) involvement in von Reckling-
hausen's disease occurs in three principal forms i) hyper-
plasia of the submucosal and myenteric nerve plexuses
and mucosal ganglioneuromatosis, which leads to disor-
dered gut motility; ii) gastrointestinal stromal tumours
showing varying degrees of neural or smooth muscle dif-
ferentiation; and iii) a distinctive glandular, somatostatin-
rich carcinoid in periampullary region of the duodenum
that contains psammoma bodies and may be associated
with phaeochromocytoma. NF-1 gene mutations involve
GTPase activating protein-coding sequences. Aberrations
in other parts of NF1 gene, or in other genes, may also be
involved in the development of the varied clinical
manifestations.
GISTs are the most common mesenchymal tumours of the
gastrointestinal (GI) tract. They are defined as c-kit
(CD117, stem cell/ mast cell growth factor receptor)-pos-
itive mesenchymal spindle cell, epithelioid or rarely pleo-
morphic neoplasms arising primarily in the
gastrointestinal tract, omentum, and mesentery [8]. A dis-
tinctive histological finding, principally in lesions of the
small intestine, is presence of scattered eosinophilic bod-
ies that range from 35 to 50 µm in size. These stain with
PAS and Masson's trichrome, and are interpreted as skei-
noid fibres, the distinctive extracellular collagen globules
originally described by Min [9]. Tumours with a high
mitotic index (>5 mitoses/10 HPF), measuring more than
Photomicrograph showing Gastrointestinal stromal tumours Figure 2
Photomicrograph showing Gastrointestinal stromal tumours a) Bland spindle cells arranged in a storiform pattern set within 
muscle wall with no necrosis, mitotic figures or pleomorphism seen. (Haematoxylin and Eosin × 100) b) Positive staining with 
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5 cms in diameter and extra-gastrointestinal spread are
considered malignant [10,11]. DNA studies show benign
tumours to be euploid while the malignant tumours are
aneuploid [12]. Intra-abdominal spread or liver metasta-
sis occurs in 10%–30%.
The association of GIST with NF-1, skeinoid fibres and an
ultrastructure suggestive of partial neural differentiation,
could indicate a mixed neural ICC related phenotype or
the possibility of ICC having neural phenotype [4]. GISTs
differ clinically and pathogenetically from true leiomyosa-
rcomas (rare in the GI tract) and leiomyomas. The latter
occur in the GI tract, predominantly in the oesophagus
(intramural tumours) and the colon and rectum (muscu-
laris mucosae tumours). GISTs differ histologically,
immunohistochemically and genetically from typical
(oesophageal) leiomyomas that are negative for c-kit and
CD34 and show neither DNA-loss at 14q, nor c-kit muta-
tions. Schwannomas on the other hand are S100-positive
benign spindle cell tumours and usually occur in stom-
ach. GI autonomic nerve tumours (GANTs) are probably
a subset of GIST, while angiosarcomas and metastatic
melanomas, both of which are often c-kit positive should
not be confused with GISTs [13].
Niv Y et al have reported a case of pancreatic cancer, duo-
denal cancer and liver metastasis in a patient with neurofi-
bromatosis [14]. Though biopsies from all these lesions
showed adenocarcinoma, the organ of origin could not be
ascertained in their study [14]. Management of synchro-
nous tumours present as a diagnostic and therapeutic
dilemma, it is important to accurately distinguish
between GIST, carcinoid tumours, and adenocarcinoma
as the prognosis of these tumours differs significantly.
Small benign tumours are often found incidentally during
unrelated surgery or autopsy [15] as in the present case. As
the occurrence is rare the optimal management still eludes
surgeons.
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